Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Did Thryv (NASDAQ:THRY) Take a USD 94.8 Million Impairment as It Sells Print Directories for USD 142 Million?

Key HighlightsThryv Holdings (NASDAQ:THRY) reported a third-quarter 2026 net loss of USD 116.0 million, or USD 2.61 per diluted share, on November 9, including a USD 94.8 million non-cashGoodwillimpairment.ConsolidatedRevenuefell 13.5% to USD 118.9 million from USD 137.4 million and missed forecasts, as the print …

Vinay Lochav | 10 November 2026

Can USA Rare Earth (NASDAQ:USAR) Turn First Serra Verde Shipments and USD 3.0 Million of Revenue Into Scale?

Key HighlightsUSA Rare Earth (NASDAQ:USAR) reported third-quarter 2026Revenueof USD 3.0 million on November 9, its first full quarter of commercial magnet sales, against no revenue a year earlier.The Serra Verde project in Brazil made its first commercial-scale shipments of mixed rare earth concentrate in …

Vinay Lochav | 10 November 2026

Why Did Repay (NASDAQ:RPAY) Cut Normalized Organic Growth Guidance to 5% to 6% Despite 97% Revenue Growth?

Key HighlightsRepay Holdings (NASDAQ:RPAY) lowered its 2026 normalized organic growth outlook to 5% to 6% from 7% to 9% on November 9, 2026, excluding political media.Third-quarterRevenuerose 97% to USD 153.4 million, but KUBRA, acquired on June 1, 2026, contributed USD 65.1 million of that …

Vinay Lochav | 10 November 2026

Could Viridian (NASDAQ:VRDN) VRDN-008 Become an Every-8-Week FcRn Drug After a 74% IgG Cut?

In chronic autoimmune diseases such as myasthenia gravis, patients may need treatment for years. A drug given every eight weeks under the skin, rather than weekly infusions or injections, would be a clear convenience advantage and could support adoption if efficacy is comparable. The …

Vinay Lochav | 10 November 2026

Is Roivant (NASDAQ:ROIV) LISRAYA Launch Off to a Strong Start With USD 31 Million in Five Weeks?

Roivant's majority-owned Immunovant unit reported that a 600 milligram dose of IMVT-1402, an FcRn inhibitor, met the primary endpoint in a potentially registrational study in difficult-to-treat rheumatoid arthritis. At week 28, 92.5% of patients on that dose achieved an ACR20 response against 75.6% on …

Vinay Lochav | 10 November 2026

Why Is Comcast (NASDAQ:CMCSA) Giving Xfinity Customers a Free 15-Day WiFi Boost for GTA VI?

The promotion is small in financial terms, but it speaks to a bigger issue. Comcast's broadbandBusinesshas faced intense competition from fixed wireless services offered by mobile carriers and from fiber builders, and the company has been working to slow customer losses. Free upgrades for …

Vinay Lochav | 10 November 2026

Why Was Tripadvisor (NASDAQ:TRIP) Upgraded to Hold Near a USD 6.95 Low Despite Lower Estimates?

Tripadvisor reported third-quarter 2026 revenue of USD 436.4 million against about USD 453.2 million expected, and adjusted earnings of USD 0.37 per share against USD 0.45. Weakness was concentrated in the Hotels and Other segment, where search-driven traffic has come under pressure from changes …

Vinay Lochav | 10 November 2026

Why Was Treace Medical (NASDAQ:TMCI) Upgraded to Buy With a USD 6.50 Target?

The third quarter gave the thesis some support. Revenue beat consensus for the twelfth quarter in a row, and adjusted EBITDA was positive at USD 0.3 million. That matters because the fourth quarter is seasonally the strongest for elective surgery, as patients use remaining …

Vinay Lochav | 10 November 2026

Top 5 More Pre-Market Losers on Tuesday: Karyopharm Therapeutics (NASDAQ:KPTI) -22.25%, Wellchange (NASDAQ:WCT) -22.15%, Groupon (NASDAQ:GRPN) -19.75%, Vivakor (NASDAQ:VIVK) -19.4%, Amaero (NASDAQ:AMRO) -18.2%

Key HighlightsKaryopharm Therapeutics (NASDAQ:KPTI) is down 22.25% at USD 0.0311 after a Chapter 11 filing on November 2, 2026, aNasdaqdelisting notice and a plan that gives common stockholders no payment.Wellchange (NASDAQ:WCT) is down 22.15% at USD 3.48 from a calculated USD 4.47, the second …

Vinay Lochav | 10 November 2026

Why Did Edesa Biotech (NASDAQ:EDSA) Jump 38.63% on a USD 12 Million Japan Licensing Deal?

Key HighlightsEdesa Biotech (NASDAQ:EDSA) shares rose 38.63%, or USD 0.83, to USD 2.97 on November 9, 2026 after the company licensed its ARDS drug candidate in Japan to Kyorin Pharmaceutical.Edesa receives USD 12 million upfront and is eligible for up to about USD 134 …

Vinay Lochav | 10 November 2026
Support

Hi! How can we help you today?

Loading…